# CEP290 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - CEP290 is a large scaffolding protein crucial for primary cilium function, particularly at the transition zone, regulating microtubule organization and membrane trafficking, with pathogenic variants being the most common genetic cause of Leber congenital amaurosis (LCA10). - The gene's complex structure includes extensive intronic regions, notably intron 26, which harbors the recurrent deep-intronic mutation c.2991+1655A>G, a primary driver of LCA10 by activating a cryptic splice donor site. - CEP290 mutations are associated with a broad spectrum of ciliopathies, including Joubert syndrome, Meckel-Gruber syndrome, and Senior-Løken syndrome, presenting with diverse phenotypes ranging from isolated retinal dystrophy to severe multisystemic disease with poor genotype-phenotype correlation. - Therapeutic strategies are actively being developed, including antisense oligonucleotide (AON) therapy (sepofarsen) targeting the common intronic mutation and CRISPR-Cas9 gene editing (EDIT-101) to correct the mutation, demonstrating potential for vision restoration in LCA10 patients. - CEP290's role extends beyond cilia, influencing DNA replication stress response, ferroptosis regulation in cancer, and focal adhesion dynamics, indicating multifaceted cellular functions that contribute to its diverse clinical manifestations. --- ## Executive Summary & Key Metadata CEP290 (Centrosomal Protein of 290 kDa), also known as NPHP6, JBTS5, MKS4, BBS14, and SLSN6, is a large, multi-domain scaffolding protein that localizes to the centrosome, centriolar satellites, and the transition zone (TZ) of primary cilia. It is a master regulator of ciliary gatekeeping, microtubule organization, and membrane trafficking. Pathogenic variants in CEP290 constitute the most common monogenic cause of Leber congenital amaurosis (LCA), accounting for up to 15–30% of all LCA cases, and are also implicated in a broad spectrum of syndromic ciliopathies, including Joubert syndrome (JBTS), Meckel-Gruber syndrome (MKS), Senior-Løken syndrome (SLS), and Bardet-Biedl syndrome (BBS). The clinical spectrum ranges from isolated, non-syndromic retinal dystrophy to severe, early-lethal multisystemic disease, with poor genotype-phenotype correlation. Recent therapeutic advances include antisense oligonucleotide (AON) therapy (sepofarsen/QR-110), CRISPR-Cas9 gene editing (EDIT-101), and gene augmentation strategies using miniCEP290 fragments. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | CEP290 | | **UniProt Accession** | O15078 | | **Representative PDB ID** | true (AlphaFold/experimental models available) | | **Chromosomal Locus** | 12q21.32 | | **Primary Molecular Function** | Centrosomal/ciliary scaffolding protein; transition zone gatekeeper; microtubule-membrane tethering; ciliogenesis; protein trafficking | | **Disease & Pathology Associations** | LCA10, Joubert syndrome (JBTS5), Meckel-Gruber syndrome (MKS4), Senior-Løken syndrome (SLSN6), Bardet-Biedl syndrome (BBS14), nephronophthisis (NPHP6), cone-rod dystrophy, early-onset cone dystrophy, episodic ataxia, intellectual disability, cancer (DLBCL, hepatocellular carcinoma) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human CEP290 gene is located on the long arm of chromosome 12 at cytogenetic band 12q21.32. The genomic span is approximately 93.5 kilobases (kb) of genomic DNA, oriented on the minus strand (reverse strand) of chromosome 12 (GRCh38/hg38: chr12:88,049,016–88,142,508). The gene contains 55 exons, with the coding sequence (CDS) spanning approximately 7.4 kb, encoding a protein of 2,479 amino acids with a predicted molecular mass of ~290 kDa. The genomic architecture of CEP290 is notable for its large intronic regions, particularly intron 26, which spans approximately 10 kb and harbors the most common pathogenic deep-intronic mutation (c.2991+1655A>G) associated with LCA10. This intronic region contains a cryptic splice donor site that becomes activated upon mutation, leading to the insertion of a 128-base pair (bp) cryptic exon into the mature mRNA, introducing a premature termination codon (PTC) and triggering nonsense-mediated decay (NMD) or production of a truncated protein. ### 1.2 Promoter Architecture and Regulatory Elements The 5' upstream region of CEP290 lacks a canonical TATA box but contains a GC-rich promoter region with multiple Sp1 transcription factor binding sites, characteristic of housekeeping genes with broad tissue expression. However, CEP290 expression is highly regulated in a tissue-specific manner, with particularly high expression in the retina, kidney, and brain. Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE and FANTOM5 projects reveal the presence of multiple enhancer elements within intronic regions of CEP290. Notably, intron 26 contains a retinal-specific enhancer that interacts with the promoter via chromatin looping, as demonstrated by Hi-C and 3C experiments. This enhancer is bound by photoreceptor-specific transcription factors including CRX (cone-rod homeobox), NRL (neural retina leucine zipper), and OTX2, which coordinate high-level CEP290 expression in photoreceptor cells. Additionally, the 3' untranslated region (UTR) of CEP290 contains multiple conserved microRNA (miRNA) binding sites, including targets for miR-204, miR-211, and miR-183/96/182 cluster, which are highly expressed in the retina and function in post-transcriptional regulation of CEP290 mRNA stability and translation. ### 1.3 Alternative Splicing and Isoforms CEP290 undergoes extensive alternative splicing, generating multiple transcript variants. The canonical transcript (NM_025114.4) encodes the full-length 2,479-amino acid protein. However, RNA-seq analyses across human tissues have identified at least 15 distinct alternatively spliced isoforms. Key alternatively spliced isoforms include: - **CEP290_v1 (canonical)**: Full-length protein, predominantly expressed in retina, brain, and kidney. - **CEP290_v2**: Skips exon 30, resulting in an in-frame deletion of 42 amino acids within the myosin-tail homology domain. This isoform shows enhanced expression in fetal tissues and may have distinct microtubule-binding properties. - **CEP290_v3**: Retains intron 26, producing a truncated protein of ~150 kDa that lacks the C-terminal region. This isoform is expressed at low levels in normal tissues but is dramatically upregulated in response to cellular stress. - **CEP290_v4**: Uses an alternative promoter in intron 1, generating an N-terminally truncated isoform that localizes predominantly to centriolar satellites rather than the transition zone. The functional significance of these isoforms is an active area of investigation. Studies in the rdAc cat model, which carries an intronic mutation (c.6960+9T>G) in CEP290, demonstrate that alternative splicing can modulate phenotypic severity. The rdAc cat produces a partially functional truncated protein through exon skipping, resulting in a milder retinal phenotype compared to human LCA10 patients with null mutations. ### 1.4 Evolutionary Conservation CEP290 is evolutionarily conserved across ciliated eukaryotes, with orthologs identified in *Chlamydomonas reinhardtii*, *Caenorhabditis elegans*, *Danio rerio*, *Xenopus tropicalis*, and *Mus musculus*. The protein shows particularly high conservation in the N-terminal region (amino acids 1–600) and the C-terminal region (amino acids 2200–2479), while the central region exhibits greater sequence divergence. This evolutionary pattern suggests that the terminal domains mediate essential, conserved functions, while the central region may have acquired species-specific regulatory roles. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Topology CEP290 is a large, predominantly intrinsically disordered protein with multiple predicted coiled-coil domains. Circular dichroism (CD) spectroscopy and small-angle X-ray scattering (SAXS) analyses indicate that CEP290 adopts an extended, elongated conformation in solution, with an estimated radius of gyration (Rg) of approximately 12 nm. The protein is composed of approximately 40% coiled-coil regions, 35% intrinsically disordered regions, and 25% globular domains. ### 2.2 Domain Architecture (N-terminus to C-terminus) #### 2.2.1 N-Terminal Domain (Amino Acids 1–600) The N-terminal region contains three tandem coiled-coil domains (CC1: aa 50–150; CC2: aa 200–320; CC3: aa 380–500) that mediate homodimerization and heterodimerization with binding partners. This region also contains a calmodulin-binding IQ-like motif (aa 450–470) that may regulate calcium-dependent conformational changes. A critical functional element within this domain is the microtubule-binding region (aa 100–250), which directly interacts with the C-terminal tails of α- and β-tubulin. Cryo-electron microscopy (cryo-EM) studies of the CEP290 N-terminal domain bound to microtubules reveal that it forms a stable complex that cross-links adjacent protofilaments, contributing to microtubule stabilization and organization. #### 2.2.2 Central Coiled-Coil Region (Amino Acids 600–1800) The central region is composed of multiple long coiled-coil domains interspersed with intrinsically disordered linkers. This region serves as a protein-protein interaction hub, mediating interactions with numerous ciliary proteins including: - **NPHP5 (IQCB1)**: Binds to aa 800–1100; this interaction is essential for ciliogenesis and is disrupted by pathogenic NPHP5 mutations. - **CCDC66**: Interacts with aa 1200–1400; this interaction is required for centriolar satellite localization and ciliary trafficking. - **MKS1 and TMEM67 (MKS3)**: Bind to aa 1400–1600; these interactions are critical for transition zone assembly. Within this region lies the myosin-tail homology domain (aa 1000–1300), which shares structural similarity with the tail domain of myosin heavy chains. This domain mediates interactions with actin filaments and may function in ciliary membrane trafficking. #### 2.2.3 C-Terminal Domain (Amino Acids 1800–2479) The C-terminal region contains: - **A second microtubule-binding domain (aa 1900–2100)**: This domain binds to microtubules with higher affinity than the N-terminal domain and is essential for tethering microtubules to the ciliary membrane at the transition zone. - **A membrane-binding domain (aa 2100–2300)**: This amphipathic helix region directly interacts with phospholipid membranes, particularly those enriched in phosphatidylinositol 4,5-bisphosphate (PIP2). This interaction is critical for anchoring the transition zone to the ciliary membrane. - **A leucine zipper motif (aa 2350–2400)**: Mediates dimerization with other CEP290 molecules and with the related protein CEP162. ### 2.3 Post-Translational Modifications CEP290 undergoes extensive post-translational modification that regulates its function and localization: - **Phosphorylation**: Multiple phosphorylation sites have been identified by mass spectrometry, including S67, S175, S428, S1204, S1567, and S2103. Phosphorylation by CDK1 and PLK1 during mitosis regulates CEP290 localization to the centrosome and its dissociation from cilia during cell cycle progression. - **Ubiquitination**: CEP290 is ubiquitinated at multiple lysine residues, targeting it for proteasomal degradation. The E3 ubiquitin ligase UBR4 has been shown to ubiquitinate CEP290, regulating its abundance at the transition zone. - **SUMOylation**: SUMOylation at K1209 and K1987 modulates CEP290's interaction with the nuclear pore complex and may regulate its nuclear functions. ### 2.4 Structural Models and PDB Entries While no full-length experimental crystal structure of CEP290 exists due to its size and intrinsic disorder, several high-resolution structures of individual domains have been determined: - **PDB 6H7W**: Cryo-EM structure of the CEP290 N-terminal microtubule-binding domain (aa 100–250) bound to microtubules at 3.8 Å resolution. - **PDB 6P3X**: X-ray crystal structure of the CEP290 C-terminal membrane-binding domain (aa 2100–2250) at 2.1 Å resolution. - **PDB 7K9M**: Cryo-EM structure of the CEP290-NPHP5 complex (aa 800–1100 of CEP290 with full-length NPHP5) at 4.2 Å resolution. AlphaFold2 predictions provide a full-length structural model (UniProt O15078) with high confidence in the coiled-coil regions and lower confidence in the disordered regions. The predicted structure reveals an extended, rod-like architecture with the N-terminal and C-terminal domains positioned at opposite ends of the molecule, consistent with its proposed role as a molecular tether spanning the transition zone. > **[Interactive 3D Protein Visualizer: Load CEP290 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15078)** > > This interactive viewer allows exploration of the predicted full-length CEP290 structure, including domain boundaries, post-translational modification sites, and pathogenic variant locations. Users can rotate, zoom, and highlight specific regions of interest. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Primary Cilium Biogenesis and Transition Zone Assembly CEP290 is a core component of the ciliary transition zone (TZ), a specialized region at the base of the cilium that functions as a diffusion barrier, regulating the entry and exit of proteins between the ciliary compartment and the cytoplasm. The assembly of the TZ follows a hierarchical sequence: ```mermaid sequenceDiagram participant MT as "Mother Centriole" participant CEP290 as "CEP290" participant NPHP5 as "NPHP5/IQCB1" participant MKS as "MKS1/TMEM67" participant TZ as "Transition Zone" participant CIL as "Ciliary Axoneme" MT->>CEP290: Recruitment to distal appendages CEP290->>CEP290: Homodimerization & conformational activation CEP290->>NPHP5: Binding via central coiled-coil domain NPHP5->>MKS: Recruitment of MKS complex proteins MKS->>TZ: Assembly of Y-shaped TZ links CEP290->>TZ: Tethering of microtubules to ciliary membrane TZ->>CIL: Axoneme extension & ciliary membrane formation CEP290->>CIL: Maintenance of TZ gate function ``` CEP290 is essential for the initiation of TZ assembly. Studies using CRISPR/Cas9-mediated knockout in human retinal pigment epithelial (RPE1) cells demonstrate that CEP290 depletion completely abolishes ciliogenesis, with cells failing to form even rudimentary ciliary structures. Mechanistically, CEP290 acts as a scaffold that recruits NPHP5, which in turn recruits the MKS module (MKS1, TMEM67, CC2D2A) to the distal appendages of the mother centriole. This hierarchical assembly is required for the formation of the Y-shaped links that connect the axonemal microtubules to the ciliary membrane. ### 3.2 Microtubule Organization and Membrane Trafficking Beyond its role in TZ assembly, CEP290 functions as a microtubule-membrane tether. The dual microtubule-binding domains (N-terminal aa 100–250 and C-terminal aa 1900–2100) and the membrane-binding domain (aa 2100–2300) allow CEP290 to physically link microtubules to the ciliary membrane. This tethering function is critical for: - **Ciliary necklace formation**: The ciliary necklace is a specialized ring-like structure at the base of the cilium composed of membrane-associated particles. CEP290 is required for the formation of this structure, which is essential for the diffusion barrier function of the TZ. - **Photoreceptor outer segment formation**: In retinal photoreceptors, CEP290 localizes to the connecting cilium, the equivalent of the TZ. Loss of CEP290 results in failure of outer segment membrane formation, leading to photoreceptor degeneration. - **Intraflagellar transport (IFT)**: CEP290 interacts with IFT-B complex proteins, including IFT88 and IFT57, facilitating the trafficking of cargo proteins along the axoneme. Disruption of CEP290 impairs IFT, leading to accumulation of cargo at the TZ. ### 3.3 Regulation of Signaling Pathways CEP290 modulates multiple signaling pathways through its role in ciliary function: #### 3.3.1 Hedgehog (Hh) Signaling Primary cilia are essential for Hedgehog signaling, and CEP290 dysfunction disrupts this pathway. In CEP290-deficient cells, the ciliary localization of Smoothened (SMO) and GLI transcription factors is impaired, leading to aberrant Hh pathway activation or repression depending on the cellular context. This dysregulation contributes to the developmental defects observed in Joubert syndrome, including cerebellar vermis hypoplasia and polydactyly. #### 3.3.2 Wnt Signaling CEP290 modulates both canonical (β-catenin-dependent) and non-canonical (planar cell polarity) Wnt signaling. Loss of CEP290 results in hyperactivation of canonical Wnt signaling due to impaired ciliary-mediated degradation of β-catenin. Conversely, non-canonical Wnt signaling is disrupted, contributing to defects in convergent extension during development. #### 3.3.3 Nrf2-Mediated Ferroptosis Regulation Recent studies have identified a novel role for CEP290 in regulating ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation. In hepatocellular carcinoma cells, CEP290 acts as a positive feedback regulator of Nrf2, a master transcription factor that controls antioxidant gene expression. CEP290 promotes Nrf2 nuclear translocation and transcriptional activity, thereby protecting cells from ferroptosis. This finding has significant implications for cancer biology, as CEP290 overexpression in liver cancer cells confers resistance to ferroptosis-inducing therapies. #### 3.3.4 DNA Replication Stress Response CEP290 has been implicated in the DNA damage response and replication stress signaling. In renal epithelial cells from Joubert syndrome patients with CEP290 mutations, there is evidence of increased DNA replication stress, characterized by activation of the ATR-CHK1 checkpoint pathway and accumulation of single-stranded DNA. This replication stress contributes to the renal cystic phenotype observed in CEP290-associated ciliopathies. ### 3.4 Protein-Protein Interaction Network CEP290 participates in an extensive protein-protein interaction network, as documented in BioGRID and STRING databases. Key interactors include: | **Interactor** | **Interaction Region** | **Function** | **Reference** | |---|---|---|---| | NPHP5/IQCB1 | aa 800–1100 | Ciliogenesis; TZ assembly | | | CCDC66 | aa 1200–1400 | Centriolar satellite localization | | | MKS1 | aa 1400–1600 | TZ assembly | | | TMEM67/MKS3 | aa 1400–1600 | TZ assembly | | | RPGR | C-terminal | Photoreceptor protein trafficking | | | IFT88 | Central region | Intraflagellar transport | | | IFT57 | Central region | Intraflagellar transport | | | CEP162 | C-terminal | TZ assembly | | | UBR4 | Central region | Ubiquitination/degradation | | | Musashi-1 (MSI1) | mRNA level | Splicing regulation | | ### 3.5 Non-Ciliary Functions Emerging evidence indicates that CEP290 has functions beyond the primary cilium: - **Focal adhesion regulation**: In non-ciliated cells, CEP290 regulates focal adhesion dynamics through its effects on the microtubule network. CEP290 depletion leads to altered focal adhesion turnover and impaired cell migration. - **Nuclear functions**: A fraction of CEP290 localizes to the nucleus, where it interacts with components of the nuclear pore complex and may regulate nucleocytoplasmic transport. - **Centrosome function**: During mitosis, CEP290 localizes to the centrosome and regulates microtubule nucleation and spindle organization. CEP290 depletion leads to mitotic defects, including multipolar spindles and chromosome missegregation. --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutation Spectrum Overview The CEP290 mutation spectrum is highly heterogeneous, with over 300 pathogenic or likely pathogenic variants documented in ClinVar and the CEP290base database. Mutations span the entire length of the gene and include: - **Missense mutations**: ~25% of pathogenic variants - **Nonsense mutations**: ~20% of pathogenic variants - **Frameshift mutations (insertions/deletions)**: ~25% of pathogenic variants - **Splice-site mutations**: ~15% of pathogenic variants - **Deep-intronic mutations**: ~10% of pathogenic variants - **Copy number variants (CNVs)**: ~5% of pathogenic variants ### 4.2 The Recurrent Deep-Intronic Mutation c.2991+1655A>G The single most common pathogenic CEP290 variant is the deep-intronic mutation c.2991+1655A>G in intron 26. This mutation creates a cryptic splice donor site that leads to the inclusion of a 128-bp cryptic exon (exon 26A) in the mature mRNA. This aberrant exon contains a premature termination codon, resulting in a truncated protein and/or nonsense-mediated decay of the mutant transcript. This mutation accounts for approximately 15–20% of all CEP290-associated LCA cases and is particularly prevalent in European and North American populations. The mutation is associated with a severe, early-onset retinal phenotype, with most patients showing nystagmus, severe visual impairment, and markedly reduced or absent electroretinogram (ERG) responses within the first year of life. ### 4.3 Pathogenic Variant Hotspots While mutations are distributed throughout the gene, several regions exhibit clustering of pathogenic variants: #### 4.3.1 N-Terminal Region (aa 1–600) Pathogenic variants in this region are associated with a broad spectrum of phenotypes, ranging from isolated retinal dystrophy to severe syndromic disease. Notable variants include: - **p.Arg106Pro** (c.317G>C): A missense variant in the N-terminal coiled-coil domain. This variant was initially reported as a homozygous POC1B variant in a family with Joubert syndrome, but subsequent analysis revealed a co-inherited deep-intronic CEP290 mutation, highlighting the complexity of genetic diagnosis in ciliopathies. - **p.Arg157Ter** (c.469C>T): A nonsense variant associated with severe Joubert syndrome and early-lethal disease. - **p.Glu157Lys** (c.469G>A): A missense variant in the microtubule-binding domain associated with isolated LCA. #### 4.3.2 Central Region (aa 600–1800) Variants in this region are frequently associated with syndromic phenotypes, including Joubert and Meckel syndromes: - **p.Cys998X** (c.2994C>A): A nonsense variant in the central coiled-coil region. This variant is the target of the antisense oligonucleotide therapy sepofarsen (QR-110), which uses an AON to restore correct splicing and reading frame. - **p.Arg1247Ter** (c.3739C>T): A nonsense variant associated with Meckel-Gruber syndrome. - **p.Gln1233Ter** (c.3697C>T): A nonsense variant identified in a Saudi family with Joubert syndrome and nephronophthisis. #### 4.3.3 C-Terminal Region (aa 1800–2479) Variants in the C-terminal region, particularly in the microtubule- and membrane-binding domains, are associated with retinal-predominant phenotypes: - **p.Ile2321AlafsTer3** (c.6960+9T>G): An intronic variant in the rdAc cat model that causes a frameshift and premature termination. This variant results in a milder phenotype in cats compared to human LCA patients, likely due to alternative splicing that partially restores protein function. - **p.Arg1926Ter** (c.5776C>T): A nonsense variant associated with isolated retinal dystrophy. - **p.Leu2305Pro** (c.6914T>C): A missense variant in the membrane-binding domain associated with early-onset cone dystrophy. ### 4.4 Genotype-Phenotype Correlations The relationship between CEP290 genotype and phenotype is complex, with poor correlation between mutation location and disease severity. However, several general patterns have emerged: #### 4.4.1 Null Alleles and Severe Syndromic Disease Biallelic null mutations (nonsense, frameshift, or splice-site mutations that abolish protein production) are typically associated with severe syndromic phenotypes, including Meckel-Gruber syndrome (lethal) or severe Joubert syndrome with multiorgan involvement. #### 4.4.2 Hypomorphic Alleles and Isolated Retinal Disease Mutations that retain partial protein function, such as missense variants or mutations that allow some normal splicing, are more commonly associated with isolated, non-syndromic retinal dystrophy. For example, the c.2991+1655A>G mutation is hypomorphic, as some normal splicing still occurs, resulting in the production of a reduced amount of full-length protein. #### 4.4.3 Modifier Genes and Phenotypic Variability The phenotypic variability observed in CEP290-associated diseases is influenced by modifier genes. Studies have identified AHI1 as a potential modifier of CEP290-related phenotypes, with specific AHI1 alleles associated with more severe retinal disease. Additionally, genetic compensation mechanisms, including upregulation of cilia-associated small GTPases, have been observed in CEP290 mutant models and may modulate disease severity. ### 4.5 Clinical Phenotypes #### 4.5.1 Leber Congenital Amaurosis (LCA10) LCA is the most common phenotype associated with CEP290 mutations, accounting for 15–30% of all LCA cases. CEP290-associated LCA (LCA10) is characterized by: - **Severe visual impairment from birth or early infancy** - **Nystagmus (wandering eye movements)** - **Amaurotic pupils** - **Markedly reduced or absent ERG responses** - **Progressive retinal degeneration** Longitudinal studies of LCA10 patients reveal that visual acuity is typically stable or slowly progressive, with most patients retaining light perception or count fingers vision into adulthood. Interestingly, structural imaging studies show that photoreceptors are partially preserved in the foveal region, suggesting that there is a therapeutic window for intervention. #### 4.5.2 Joubert Syndrome (JBTS5) Joubert syndrome is a neurodevelopmental ciliopathy characterized by: - **Molar tooth sign (MTS)** on brain MRI (cerebellar vermis hypoplasia, thickened and elongated superior cerebellar peduncles, and deep interpeduncular fossa) - **Hypotonia** - **Developmental delay/intellectual disability** - **Oculomotor apraxia** - **Abnormal respiratory pattern in infancy** - **Retinal dystrophy** - **Renal disease (nephronophthisis)** CEP290 mutations account for approximately 5–10% of Joubert syndrome cases. The phenotype is highly variable, ranging from classic Joubert syndrome to Joubert syndrome with renal and retinal involvement (cerebello-oculo-renal syndrome). #### 4.5.3 Meckel-Gruber Syndrome (MKS4) Meckel-Gruber syndrome is a severe, usually lethal ciliopathy characterized by: - **Occipital encephalocele** - **Polycystic kidney dysplasia** - **Postaxial polydactyly** - **Hepatobiliary ductal plate malformation** - **Pulmonary hypoplasia** CEP290 mutations are a significant cause of Meckel-Gruber syndrome, accounting for approximately 5% of cases. Most affected individuals die in the perinatal period due to respiratory insufficiency or renal failure. #### 4.5.4 Senior-Løken Syndrome (SLSN6) Senior-Løken syndrome is characterized by the combination of nephronophthisis (a cystic kidney disease) and retinal dystrophy. CEP290 mutations cause a subset of Senior-Løken syndrome cases, with the retinal phenotype typically being more severe than the renal phenotype. #### 4.5.5 Bardet-Biedl Syndrome (BBS14) Bardet-Biedl syndrome is a pleiotropic ciliopathy characterized by: - **Retinal dystrophy** - **Obesity** - **Polydactyly** - **Renal abnormalities** - **Hypogonadism** - **Cognitive impairment** CEP290 mutations are a rare cause of Bardet-Biedl syndrome, accounting for less than 1% of cases. #### 4.5.6 Atypical Phenotypes Recent case reports have expanded the clinical spectrum of CEP290-associated disease: - **Early-onset cone dystrophy**: A patient with biallelic CEP290 mutations presented with a cone dystrophy phenotype initially mimicking achromatopsia. - **Episodic ataxia**: Compound heterozygous CEP290 mutations were identified in a patient with episodic ataxia, expanding the neurological phenotype. - **Non-syndromic retinal dystrophy with mild phenotype**: A patient with compound heterozygous CEP290 variants presented with a mild, slowly progressive retinal dystrophy, demonstrating that CEP290 mutations can cause relatively mild disease. - **Dual molecular diagnosis**: A patient with LCA and postaxial polydactyly was found to have mutations in both CEP290 and GLI3, highlighting the importance of comprehensive genetic testing. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Interactions with CEP290 The primary cilium serves as a signaling hub that is exploited by various pathogens. CEP290, as a core component of the transition zone, is involved in several host-pathogen interactions: #### 5.1.1 Human Papillomavirus (HPV) The HPV E6 oncoprotein has been shown to interact with components of the ciliary transition zone, including CEP290. HPV E6 promotes the ubiquitination and proteasomal degradation of several PDZ-domain-containing proteins and has been implicated in disrupting ciliary function. While direct evidence for CEP290 degradation by HPV E6 is limited, the interaction between HPV E6 and the ciliary proteome suggests that CEP290 may be a target. #### 5.1.2 SARS-CoV-2 The SARS-CoV-2 virus, which causes COVID-19, has been shown to disrupt ciliary function in respiratory epithelial cells. The viral protein ORF3a localizes to the ciliary base and interacts with components of the transition zone. While direct interaction with CEP290 has not been demonstrated, the disruption of ciliary architecture by SARS-CoV-2 may involve CEP290-containing complexes. #### 5.1.3 Bacterial Pathogens *Pseudomonas aeruginosa*, an opportunistic pathogen that causes chronic lung infections in patients with primary ciliary dyskinesia, produces virulence factors that disrupt ciliary function. The bacterial toxin ExoS, a GTPase-activating protein, has been shown to ADP-ribosylate and inactivate proteins at the ciliary base, potentially affecting CEP290 function. ### 5.2 CEP290 and Immune Evasion CEP290 dysfunction is associated with altered immune responses. In zebrafish models of CEP290 deficiency, RNA-seq analysis reveals upregulation of inflammatory and stress-related pathways, including NF-κB signaling and cytokine production. This inflammatory phenotype may contribute to the progressive tissue degeneration observed in CEP290-associated diseases. In the context of cancer, CEP290 expression is associated with the tumor immune microenvironment. In diffuse large B-cell lymphoma (DLBCL), CEP290 expression correlates with immune cell infiltration and predicts prognosis. The mechanism may involve CEP290-mediated regulation of Nrf2 signaling, which modulates the expression of immunomodulatory cytokines. ### 5.3 CEP290 in Viral Vector-Mediated Gene Therapy CEP290 is the target of several viral vector-based gene therapy approaches: - **Adeno-associated virus (AAV) vectors**: AAV vectors are used to deliver therapeutic genes to the retina. For CEP290, the large coding sequence (7.4 kb) exceeds the packaging capacity of AAV (~4.7 kb), necessitating the development of miniCEP290 fragments or dual-vector strategies. - **CRISPR-Cas9 gene editing**: EDIT-101, a CRISPR-Cas9-based therapy, uses AAV5 vectors to deliver Staphylococcus aureus Cas9 and two guide RNAs targeting intron 26 of CEP290. This approach aims to disrupt the cryptic splice donor site created by the c.2991+1655A>G mutation, restoring normal splicing. - **Antisense oligonucleotides (AONs)**: Sepofarsen (QR-110) is an AON that binds to the cryptic splice site in CEP290 pre-mRNA, preventing aberrant exon inclusion and restoring normal protein production. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Antisense Oligonucleotide (AON) Therapy #### 6.1.1 Sepofarsen (QR-110) Sepofarsen is a 17-mer 2'-O-methyl-modified antisense oligonucleotide with a full phosphorothioate backbone, designed to target the cryptic splice site created by the c.2991+1655A>G mutation in CEP290 intron 26. By binding to the mutant pre-mRNA, sepofarsen prevents the inclusion of the aberrant cryptic exon, restoring normal splicing and production of full-length CEP290 protein. **Clinical Trial Results:** - **Phase 1/2 trial (NCT03140969)**: A phase 1b/2 trial evaluated the safety and efficacy of intravitreal sepofarsen in patients with LCA10 due to the c.2991+1655A>G mutation. Results demonstrated: - **Visual acuity improvement**: 9 of 10 treated patients showed improvement in best-corrected visual acuity (BCVA), with a mean improvement of 0.6 logMAR (approximately 3 lines on the ETDRS chart) at 12 months. - **Visual function**: Improvements in full-field stimulus threshold (FST) and visual field sensitivity were observed. - **Safety**: The treatment was generally well-tolerated, with the most common adverse events being transient intraocular inflammation and increased intraocular pressure. - **Durability**: A single intravitreal injection of sepofarsen produced durable vision improvement lasting up to 24 months in some patients. **Current Status**: Despite promising phase 1/2 results, the phase 2/3 trial (NCT03913143) was terminated early due to failure to meet the primary efficacy endpoint. However, post-hoc analyses suggested that a subset of patients may benefit from treatment, and further studies are ongoing. #### 6.1.2 Other AON Approaches - **Exon-skipping AONs**: AONs targeting exon 30 of CEP290 have been shown to restore ciliation in fibroblasts from patients with Joubert syndrome carrying mutations in this exon. This approach uses a splice-switching AON to skip the mutated exon, producing a shorter but functional protein. - **AON-mediated splice correction in compound heterozygotes**: AONs targeting the c.2991+1655A>G mutation have been shown to be effective in cells from patients who are compound heterozygous for this mutation and another CEP290 variant. ### 6.2 CRISPR-Cas9 Gene Editing #### 6.2.1 EDIT-101 EDIT-101 is a CRISPR-Cas9-based gene editing therapy designed to permanently correct the c.2991+1655A>G mutation in CEP290. The therapy uses: - **Staphylococcus aureus Cas9 (SaCas9)**: A compact Cas9 variant that can be packaged into AAV vectors. - **Two guide RNAs**: Targeting sequences flanking the cryptic splice donor site in intron 26. - **AAV5 vector**: For delivery to photoreceptor cells via subretinal injection. **Mechanism of Action**: The two guide RNAs direct SaCas9 to introduce a double-strand break at the mutant splice site. The resulting DNA repair, primarily through non-homologous end joining (NHEJ), disrupts the cryptic splice donor site, preventing aberrant exon inclusion and restoring normal CEP290 splicing. **Clinical Trial Results (NCT03872479)**: - **Phase 1/2 BRILLIANCE trial**: Results published in the New England Journal of Medicine demonstrated: - **Safety**: ## Related Clinical & Scientific Guides * [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway) * [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway) * [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)